Kiran Mazumdar-Shaw built Biocon when no Indian bank wanted to lend to a 25-year-old woman

In 1978, Kiran Mazumdar-Shaw was 25 years old, newly returned from Australia with a master brewer’s qualification, and unemployable. The breweries she applied to in India said they could not hire a woman to run the floor. Two decades later, she would build the country’s first biotechnology company, Biocon, into a globally listed biopharma group with subsidiaries in Malaysia and the United States.

Her story is, on the face of it, an Indian business legend. But the more honest version is a study in patience, the patience of a founder who spent the better part of two decades doing unfashionable industrial-enzyme work before the world decided biotech was sexy.

A brewmaster nobody would hire

Kiran Mazumdar grew up in Bangalore. Her father, Rasendra Mazumdar, was the head brewmaster at United Breweries, and she followed him into the science of fermentation, training at Ballarat in Australia and qualifying as a master brewer. When she returned to India, every brewery she approached politely turned her down. They had never hired a woman for those roles before.

A chance meeting with Leslie Auchincloss, founder of Biocon Biochemicals in Cork, Ireland, gave her an alternative. Auchincloss was looking for an Indian partner to produce industrial enzymes, the kind used in food, textile and brewing applications. India’s Foreign Exchange Regulation Act at the time capped foreign holding in an Indian company at 30 per cent, so Mazumdar ended up with a 70 per cent stake in the new Indian entity, even though she had no industrial experience, no factory and almost no capital.

A garage in Bengaluru, papain from papaya

Biocon India was registered in 1978, with what has been widely reported as a starting capital of around ₹10,000. Mazumdar set up an office in the garage of a rented house in Bengaluru and began producing papain, an enzyme extracted from papaya, used in brewing and meat tenderising, and isinglass, a clarifying agent for beer.

Hiring was hard. By her own account in multiple later interviews, even hiring labour for an industrial-enzyme floor was difficult because the men she wanted to employ were reluctant to work under a woman. Indian banks were unwilling to extend credit to a company run by a 25-year-old woman with no collateral and a foreign technology partner. She has often described those early years as a series of slammed doors that eventually had to be quietly walked around.

From enzymes to insulin

Through the 1980s, Biocon built a strong industrial enzymes business and began exporting. The genuinely strategic move came when Mazumdar-Shaw decided that the future for Biocon was not in industrial enzymes but in biopharmaceuticals. In the late 1990s and 2000s, she pushed the company aggressively into statins, then biosimilars, and ultimately into recombinant insulin.

Biocon’s entry into recombinant human insulin was a watershed for Indian biotech. India had, and still has, one of the largest diabetic populations in the world, and depended overwhelmingly on imports for life-saving insulins. Biocon’s decision to manufacture insulin at scale, and later biosimilar versions of monoclonal antibodies, changed the economics of access for millions of Indian patients.

The IPO and the billionaire moment

In 2004, Biocon listed on the BSE and NSE. The IPO was oversubscribed many times over, and on listing day the company crossed a market capitalisation of over a billion dollars, making Kiran Mazumdar-Shaw one of the richest self-made women in India and, by widespread media reckoning, its first self-made woman billionaire.

Two decades later, the group has split its biologics business into a separately listed entity, Biocon Biologics, and its research-services arm, Syngene International, into another listed company, meaning Mazumdar-Shaw is now associated with a multi-entity, publicly listed biopharma family of companies across India.

The other Biocon: research, philanthropy and policy

Outside the company, Mazumdar-Shaw has become one of the most quoted Indian business voices on policy. She has been associated with key government advisory bodies on science and technology, served on global biotech committees, and is a public donor, the Mazumdar Shaw Medical Centre in Bengaluru and the Mazumdar Shaw Cancer Centre are part of her philanthropic footprint.

She is also unusually transparent about her own life. She has written and spoken publicly about losing her husband, John Shaw, former Vice-Chairman of Biocon, in October 2022, and about how she has navigated grief as a leader of a complex listed group.

“I had no money, no business experience and no background. What I had was an ability to start.”

What founders can take from the Biocon story

Biocon is older than most other companies on this site by decades, but its lessons translate forward almost too neatly for the present generation of Indian founders.

The first is that category-creation businesses are slow. Biocon spent the better part of two decades on industrial enzymes before pharma started to pay off. Founders who plan their lives around an 18-month venture cycle find this kind of patience hard. Mazumdar-Shaw’s career suggests that for some categories, biotech, deep tech, infrastructure, there is simply no shortcut to the ten-year curve.

The second is that being underestimated is a cost, not a strategy. There is no flattering way to read the story of a young woman being denied jobs and loans on gender grounds, and Mazumdar-Shaw has never pretended otherwise. What she did do is keep returning to the work. That distinction matters when newer founders romanticise adversity. She has been clear that the goal is to remove friction for the next generation, not to celebrate it.

Numbers and timeline

A few load-bearing dates and figures from the public record help anchor the Biocon story. The company was incorporated in 1978 with reported initial capital of around ₹10,000. The 2004 IPO on the BSE and NSE was oversubscribed many times over, and on listing day the market capitalisation crossed one billion US dollars, the moment widely cited as making Kiran Mazumdar-Shaw India’s first self-made woman billionaire. In the decades that followed, the research-services arm Syngene International was separately listed (2015), and Biocon Biologics, the biosimilars business, was carved out and brought into public markets in recent years. The original industrial-enzymes line that started everything in 1978 still exists, though it is no longer the centre of gravity of the group.

Frequently asked questions about Kiran Mazumdar-Shaw

Who founded Biocon?

Biocon was founded in 1978 in Bangalore by Kiran Mazumdar-Shaw, then 25 years old and trained as a master brewer at Ballarat in Australia. The company was set up as a joint venture with Biocon Biochemicals of Ireland; under India’s Foreign Exchange Regulation Act at the time, foreign holding was capped at 30%, so Mazumdar-Shaw held 70%. The Indian entity was later fully Indianised after the Irish parent’s stake was acquired, ultimately by her and her husband John Shaw via Glentec International. The fact that no Indian brewery would hire her on gender grounds is now well-documented in her own published interviews and books, and is the immediate context in which Biocon was founded. She has been the executive chairperson of the group ever since.

What does Biocon do, and how is it structured today?

Biocon is a publicly listed biopharma group with three distinct businesses. Biocon Limited is the parent and owns industrial-enzymes-era roots and small molecules. Biocon Biologics, separately listed in recent years, makes biosimilars and recombinant insulins and is the largest revenue line. Syngene International is the research-services arm, also separately listed, that runs contract research and manufacturing for global pharma clients. The split-listing structure is unusual for an Indian pharma family and reflects a deliberate choice to give each business its own balance sheet and capital story.

Why was Biocon’s 2004 IPO considered a landmark?

When Biocon listed on the BSE and NSE in 2004, the IPO was oversubscribed many times over, and on its first day of trading the market capitalisation crossed a billion dollars. That made Kiran Mazumdar-Shaw, by widespread media reckoning, India’s first self-made woman billionaire. The IPO was also a category moment for Indian biotech, until that point, biotech had been treated as a research-services or contract category by Indian capital markets. After Biocon, biotech became a recognisable consumer-facing investment story in India.

What can today’s founders learn from the Biocon story?

Two patterns stand out. The first is that category-creation businesses run on decade clocks: Biocon spent the better part of two decades on industrial enzymes before its pharma economics matured, which is incompatible with the typical 18-24 month venture cycle. The second is that being underestimated is a cost, not a strategy: being denied loans and labour at the start cost Biocon years of growth, even though it’s now retold as part of the founding myth. Mazumdar-Shaw’s public position has consistently been that the goal is to remove that friction for the next generation of women founders, not to romanticise it.

What is Kiran Mazumdar-Shaw’s net worth?

Kiran Mazumdar-Shaw has been a long-standing entry on global rich lists through her promoter holding in Biocon. Forbes has estimated her net worth at roughly $3.4 billion, and the Kotak–Hurun list put it at about ₹29,030 crore in 2022. As with any listed-company founder, the number tracks Biocon’s share price and should be read with its date and source.